Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Monopar Therapeutics Inc ( (MNPR) ) has shared an update.
On March 2, 2026, Monopar Therapeutics Inc. announced it had appointed veteran biopharma executive Susan Rodriguez as its Chief Commercial and Strategy Officer, a newly created role. Rodriguez, who has over 30 years of industry experience, will shape the company’s commercial strategy and build its infrastructure as Monopar moves its late-stage Wilson disease therapy ALXN1840 toward a planned U.S. regulatory filing.
Her appointment follows senior roles at Avadel Pharmaceuticals, Ardelyx, and Tolmar Pharmaceuticals, where she led commercial build-outs, product launches, and helped drive a multibillion-dollar acquisition. The move signals Monopar’s transition from a predominantly development-stage business to a more commercialization-ready organization, potentially strengthening its competitive position in rare diseases and enhancing prospects for ALXN1840’s eventual market launch.
The most recent analyst rating on (MNPR) stock is a Buy with a $104.00 price target. To see the full list of analyst forecasts on Monopar Therapeutics Inc stock, see the MNPR Stock Forecast page.
Spark’s Take on MNPR Stock
According to Spark, TipRanks’ AI Analyst, MNPR is a Neutral.
The score is driven primarily by mixed financial performance—strong, low-debt balance sheet but ongoing pre-revenue losses and increasing cash burn. Technicals add downside pressure due to a clear downtrend, while the recent positive Phase 2 update provides an offsetting catalyst; valuation support is limited because earnings are negative and no dividend yield is provided.
To see Spark’s full report on MNPR stock, click here.
More about Monopar Therapeutics Inc
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs. Its pipeline includes late-stage ALXN1840 for Wilson disease and several radiopharmaceutical programs, such as Phase 1-stage MNPR-101-Zr for imaging advanced cancers and early-stage MNPR-101-Lu and MNPR-101-Ac for treating advanced cancers.
The company is listed on Nasdaq under the ticker MNPR and is advancing both rare disease and oncology-focused candidates. By combining late-stage rare disease assets with early-stage radiopharmaceutical oncology programs, Monopar is positioning itself in specialized, high-value therapeutic niches within the broader biopharma sector.
Average Trading Volume: 276,014
Technical Sentiment Signal: Hold
Current Market Cap: $366.2M
See more data about MNPR stock on TipRanks’ Stock Analysis page.